ByteDance Secures $29.6 Billion Loan to Boost AI Investment 
GSM Eyes US, Europe Expansion Ahead of 2028 Hong Kong IPO 
CATL Shares Fall as Hungary Plant Faces Safety Halt 
SpaceX Mobile Network Could Cost Up to $130 Billion, Bernstein Says 
OpenAI Nears Astra AI Model Launch With Safety Focus 
GM Canada Workers Approve C$1.1 Billion Investment Deal 
BP Names Ian Tyler Permanent Chairman After Governance Shake-Up 
Microsoft to Reveal Azure Revenue in Major Reporting Shake-Up 
Audi, SAIC Launch China Innovation Hub for New AUDI Models 
Honda Targets $9.4 Billion in Cost Cuts as China EV Competition Intensifies 
MongoDB Stock Sinks 14% as Atlas Growth Misses Expectations 
Amazon Shares Fall as FTC Plans Ad Pricing Lawsuit 
Trump Says ExxonMobil Among Oil Majors Planning Venezuela Return 
Lenovo Shares Fall After Dropbox Security Breach Exposes ID Vulnerability 
Shein Shares Slide 9% in Hong Kong IPO Debut 
OpenAI Rejects Apple Trade Secret Theft Claims 
Fast Retailing Shares Drop as Uniqlo Japan August Sales Fall 
Add as a preferred source on Google
CAMBRIDGE, Mass., March 12, 2018 -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced that it will host an Analyst and Investor Day on April 11, 2018 in New York City from 8:30 a.m. – 11:00 a.m. ET. Vericel executives will provide business updates and facilitate discussions with surgeon thought leaders who currently use Vericel products in their practices. Also speaking will be world champion swimmer, best-selling author, five-time Olympian and MACI® (autologous cultured chondrocytes on porcine collagen membrane) patient Dara Torres.
The presentation will be live webcast at http://investors.vcel.com/events-presentations. For those not available to listen to the live broadcast, a replay will be archived until April 10, 2019 and available at http://investors.vcel.com/events-presentations. For more information or to RSVP please contact Kelly Mueller at [email protected].
About Vericel Corporation
Vericel is a leader in advanced cell therapies for the sports medicine and severe burn care markets. The company markets two advanced cell therapy products in the United States. MACI® is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel® (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. For more information, please visit the company's website at www.vcel.com.
Epicel® and MACI® are registered trademarks of Vericel Corporation. © 2018 Vericel Corporation. All rights reserved.
(vcel-corp)
Global Media Contacts:
David Schull
Russo Partners LLC
+1 212-845-4271 (office)
+1 858-717-2310 (mobile)
[email protected]
Karen Chase
Russo Partners LLC
+1 646-942-5627 (office)
+1 917-547-0434 (mobile)
[email protected]
Investor Contacts:
Chad Rubin
Solebury Trout
[email protected]
+1 (646) 378-2947
Lee Stern
Solebury Trout
[email protected]
+1 (646) 378-2922
